| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/05/2012 | WO2012002583A1 Method for treating schizophrenia and related diseases with a combination therapy |
| 01/05/2012 | WO2012002388A1 Drug delivery agent to sentinel lymph node |
| 01/05/2012 | WO2012001941A1 Prophylactic or ameliorating agent for genetic diseases |
| 01/05/2012 | WO2012001641A1 Stable pharmaceutical compositions |
| 01/05/2012 | WO2011141113A3 Combination of vitamin k and nicotinamide |
| 01/05/2012 | US20120005767 Antibodies to insulin-like growth factor i receptor |
| 01/05/2012 | US20120004312 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 01/05/2012 | US20120004171 Novel therapies for chronic renal failure |
| 01/05/2012 | US20120004169 Materials and methods for treatment of cancer and identification of anti-cancer compounds |
| 01/05/2012 | US20120004168 Exendins and exendin agonist analogs to regulate gastrointestinal motility |
| 01/05/2012 | US20120004158 Quaternised Ammonium Cyclodextrin Compounds |
| 01/05/2012 | US20120003340 Compositions and methods for detoxification and cancer prevention |
| 01/05/2012 | US20120003337 Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| 01/05/2012 | US20120003290 Method for reducing pain |
| 01/05/2012 | US20120003246 Novel composition and methods for the treatment of psoriasis |
| 01/05/2012 | US20120003229 Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy |
| 01/05/2012 | US20120003217 Herceptin® aduvant therapy |
| 01/05/2012 | US20120003198 Lutein/Zeaxanthin for glare protection |
| 01/05/2012 | CA2803010A1 Dissolvable fibrous web structure article comprising active agents |
| 01/04/2012 | EP2402314A1 (Aza)indole derivative and use thereof for medical purposes |
| 01/04/2012 | EP2402034A1 A method for screening for a substance having an action of proliferating natural killer cells |
| 01/04/2012 | EP2402033A1 Cell adhesion inhibitor and use thereof |
| 01/04/2012 | EP2402031A1 Immunologic adjuvant composition and use thereof |
| 01/04/2012 | EP2402019A1 Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues |
| 01/04/2012 | EP2402013A1 Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist |
| 01/04/2012 | EP2402010A1 Solid drug for oral use |
| 01/04/2012 | EP2402009A1 Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system |
| 01/04/2012 | EP2400988A1 Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin |
| 01/04/2012 | EP2400986A1 Enhanced migraine treatments based on ghrelin mimetics |
| 01/04/2012 | EP2400985A2 Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| 01/04/2012 | EP2400963A1 Compositions for use in cardioplegia comprising esmolol and adenosine |
| 01/04/2012 | EP2400962A1 Drug combinations containing pde4 inhibitors and nsaids |
| 01/04/2012 | EP2400961A1 Drug combinations containing pde4 inhibitors and nsaids |
| 01/04/2012 | EP2400959A1 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
| 01/04/2012 | EP2164492B1 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for treating schizophrenia |
| 01/04/2012 | EP2056829B1 Using pi3k and mek modulators in treatments of cancer |
| 01/04/2012 | EP1830829B1 Sphingolipids in treatment and prevention of hepatic steatosis |
| 01/04/2012 | EP1781298B1 Pharmaceutical combinations containing benzoxazine for treating respiratory diseases |
| 01/04/2012 | EP1620058B1 Composition for improving cognition and memory |
| 01/04/2012 | EP1539149B1 Combinations of metabotropic glutamate receptor antagonists and their use in treating addictive disorders |
| 01/04/2012 | EP1494649B1 Nanoparticulate megestrol formulations |
| 01/04/2012 | EP1441720B1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| 01/04/2012 | EP1422225B1 Benzoisoselenazole derivatives with anti-inflammation, antineoplastic and anti-thrombosis activity and their use |
| 01/04/2012 | EP1339663B1 Naphthalene derivatives |
| 01/04/2012 | CN102307896A Fibronectin type III domain based scaffold compositions, methods and uses |
| 01/04/2012 | CN102307857A High penetration compositions and their applications |
| 01/04/2012 | CN102307578A Methods and compositions for treating inflammation and inflammation-related pathologies |
| 01/04/2012 | CN102304110A Hydroxamates as therapeutic agents |
| 01/04/2012 | CN102302784A Tumor chemotherapeutic medicinal preparation and preparation method thereof |
| 01/04/2012 | CN102302781A Medical use of inhibitors of glutaminyl and glutamate cyclases |
| 01/04/2012 | CN102302780A Pharmaceutical composition for treating bronchial asthma |
| 01/04/2012 | CN102302779A Cream preparation used for treating phimosis, and application thereof |
| 01/04/2012 | CN102302777A Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| 01/04/2012 | CN102302668A Pharmaceutical composition for treating polycystic ovary syndrome (PCOS) |
| 01/04/2012 | CN102302494A Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 01/04/2012 | CN102302493A Methods to mobilize progenitor/stem cells |
| 01/04/2012 | CN102302492A Methods and compositions for the treatment of neuropathic pain |
| 01/04/2012 | CN102302455A Method for preparing microsphere preparation coated with hydrophilic medicaments |
| 01/04/2012 | CN101618216B Direct compression formulation and process |
| 01/04/2012 | CN101543632B Anti-tumor prodrug having accurate structure and taking novel amphipathic polymer as carrier and synthetic method thereof |
| 01/04/2012 | CN101347434B Medicament composition containing renin inhibitor and acidum folicum compound and uses thereof |
| 01/04/2012 | CN101317821B Ultra-fine dry powder particle suitable for drug administration for lung, and preparation method thereof |
| 01/03/2012 | US8088974 Production of polyunsaturated fatty acids, novel biosynthesis genes, and novel plant expression constructs |
| 01/03/2012 | US8088828 Treating benign prostate hyperplasia with SARMS |
| 01/03/2012 | US8088827 Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension |
| 01/03/2012 | US8088823 Tuberculosis treatment using pleuromutilin derivatives |
| 01/03/2012 | US8088814 Methods and compositions for the treatment of psychiatric disorders |
| 01/03/2012 | US8088813 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 01/03/2012 | US8088762 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/03/2012 | US8088410 25-hydroxy Vitamin D3 compositions |
| 01/03/2012 | US8088407 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 01/03/2012 | US8088397 Human lymphocyte vaccine adjuvant |
| 01/03/2012 | US8088396 Isolated complexes of endotoxin and modified MD-2 |
| 01/03/2012 | US8088395 Phytol derived immunoadjuvants and their use in vaccine formulations |
| 01/03/2012 | US8088388 Complexing; water in oil emulsion; immunostimulant |
| 01/03/2012 | US8088362 Salmeterol superfine formulation |
| 01/03/2012 | US8088361 Treatment of allergic rhinitis in mammals with Clostridia neurotoxins |
| 01/03/2012 | US8088360 Treatment of infectious rhinitis in mammals with clostridia neurotoxins |
| 01/03/2012 | US8088157 Methods and apparatus for stenting comprising enhanced embolic protection coupled with improved protections against restenosis and thrombus formation |
| 01/03/2012 | CA2690293C Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 01/03/2012 | CA2632556C Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 01/03/2012 | CA2512434C Sustained-release pharmaceutical composition comprising carrageenan for lung administration |
| 01/03/2012 | CA2508932C Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 01/03/2012 | CA2501610C Epothilone derivatives for the treatment of multiple myeloma |
| 01/03/2012 | CA2499622C Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
| 01/03/2012 | CA2496902C Medicament for activating the phagocytic capacity of macrophages |
| 01/03/2012 | CA2490200C 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 01/03/2012 | CA2489128C 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
| 01/03/2012 | CA2486712C Method of treating diabetes |
| 01/03/2012 | CA2466054C Apo-2 ligand/trail formulations |
| 01/03/2012 | CA2464309C Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 01/03/2012 | CA2457719C Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 01/03/2012 | CA2446254C New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
| 01/03/2012 | CA2432020C Coenzyme q products exhibiting high dissolution qualities |
| 01/03/2012 | CA2428728C Combination antiperspirant and antimicrobial compositions |
| 01/03/2012 | CA2423220C Modified prodrug forms of ap/amp |
| 01/03/2012 | CA2420618C Percarboxylated polysaccharides, and a process for their preparation |
| 01/03/2012 | CA2399293C Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| 01/03/2012 | CA2388180C Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 01/03/2012 | CA2334960C Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases |